Antibacterial and synergistic effects of enzybiotics in combination with antimicrobial peptides and outer membrane permeabilizers against Helicobacter pylori
FEMS Microbiology Letters · 2025
DOI: 10.1093/femsle/fnaf130 ↗Kurz gefasst
Fachartikel in der Zeitschrift FEMS Microbiology Letters, 2025. Verfasst von Guizi Ye und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Genetic and Development of Complex Phenotypes, School of Life Sciences, Fudan University, Shanghai 200433, China. Hauptthemen laut MEDLINE: Helicobacter pylori, Anti-Bacterial Agents, Antimicrobial Peptides, Antimicrobial Cationic Peptides. Die Arbeit nennt 30 Literaturangaben. Gefördert von: National Key Research and Development Program, Jiangsu Provincial Key Research and Development Program, Science and Technology Research Program of Shanghai.
Abstract (Originalsprache)
This study systematically evaluated the in vitro antibacterial activity, synergistic effects, and outer membrane permeabilizer-mediated enhancement of enzybiotics (AB469, lysozyme, Ply187) and antimicrobial peptides (nisin, S16) against Helicobacter pylori. To our knowledge, this is the first report demonstrating in vitro synergistic anti-Helicobacter pylori activity between engineered enzybiotics and antimicrobial peptides. Results demonstrated that AB469 exhibited the strongest antibacterial activity with a minimum inhibitory concentration (MIC) of 0.1 μM (3.9 μg/mL), significantly outperforming lysozyme (1.3 μM/19.5 μg/mL), Ply187 (1.4 μM/25 μg/mL), S16 (3.3 μM/8 μg/mL), and nisin (3.6 μM/12.5 μg/mL). Synergistic assays revealed that the combination of AB469 and lysozyme achieved the most potent synergy (FIC index = 0.249), reducing their MICs by 8-fold each. Similarly, S16 and lysozyme showed synergistic effects (FIC = 0.249), with MICs reduced by 8-fold. In contrast, nisin combined with AB469 or lysozyme displayed indifferent effects (FIC = 2.0). Additionally, outer membrane permeabilizers (EDTA-2Na, lactoferrin, and citric acid) significantly enhanced the antibacterial activity of AB469 and lysozyme. For example, EDTA-2Na, lactoferrin, and citric acid reduced AB469’s MIC by 16-fold, 8-fold, and 16-fold, respectively. This study highlights a dual-targeting strategy combining peptidoglycan degradation and outer membrane disruption, providing critical insights for combating drug-resistant H. pylori.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Genetic and Development of Complex Phenotypes, School of Life Sciences, Fudan University, Shanghai 200433, China.
- Kunshan Bio-Green Biotechnology Co., Ltd, Kunshan 215316, China.
- Shanghai High-Tech United Bio-Technological R&D Co., Ltd, Shanghai 201206, China.
- Shanghai Engineering Research Center of Industrial Microorganisms, Shanghai 200433, China.
ORCID-Profile: Guizi Ye
Förderung
- National Key Research and Development Program
- Jiangsu Provincial Key Research and Development Program
- Science and Technology Research Program of Shanghai
Zitieren
APA
Ye, G., Wu, H., Wang, W., Xie, H., Xu, Y., Fang, S., Zhong, J., & Huang, Q. (2025). Antibacterial and synergistic effects of enzybiotics in combination with antimicrobial peptides and outer membrane permeabilizers against Helicobacter pylori. FEMS Microbiology Letters. https://doi.org/10.1093/femsle/fnaf130
Vancouver
Ye G, Wu H, Wang W, Xie H, Xu Y, Fang S, et al. Antibacterial and synergistic effects of enzybiotics in combination with antimicrobial peptides and outer membrane permeabilizers against Helicobacter pylori. FEMS Microbiology Letters. 2025. doi:10.1093/femsle/fnaf130
BibTeX
@article{Ye2025,
author = {Ye, Guizi and Wu, Hongyu and Wang, Wei and Xie, Hong and Xu, Yan and Fang, Shizhen and Zhong, Jiang and Huang, Qingshan},
title = {Antibacterial and synergistic effects of enzybiotics in combination with antimicrobial peptides and outer membrane permeabilizers against Helicobacter pylori},
journal = {FEMS Microbiology Letters},
year = {2025},
doi = {10.1093/femsle/fnaf130}
}
EUVIMED